Innovation Pharmaceuticals Inc.
company.status.inactiveCIK 1355250fmd_1EXRT9YYJH42R3NXARQN7VFQ82Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2007 to Sep 30, 2023, 56 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Research and development | 6 | 11 | 9 | 13 | 11 | 4 | 3 | 7 | 5 | 1 |
| Compensation and benefits | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 8 | 13 | 13 | 15 | 14 | 6 | 5 | 9 | 7 | 3 |
| Operating income | (8) | (13) | (13) | (15) | (14) | (6) | (5) | (9) | (7) | (3) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (0) | (0) | (2) | (2) | – | – | (0) | (0) |
| Income before taxes | (8) | (13) | (13) | (16) | (16) | (9) | – | – | – | – |
| Income tax expense | – | – | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (6) | (5) | – | (6) | (2) |
| Net income | (8) | (13) | (13) | (16) | (16) | (9) | (7) | (14) | (7) | (3) |
| Net income to common shareholders | (10) | (13) | (13) | – | – | – | – | – | – | – |